5,016 Shares in Medpace Holdings, Inc. $MEDP Acquired by Diversify Advisory Services LLC

Diversify Advisory Services LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,016 shares of the company’s stock, valued at approximately $2,956,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the 4th quarter worth about $30,000. Allied Private Wealth LLC acquired a new stake in shares of Medpace during the 2nd quarter worth about $31,000. Basecamp Wealth Advisors LLC raised its holdings in Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after buying an additional 45 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace in the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Mizuho increased their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and increased their price objective for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 458 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total transaction of $274,978.62. Following the sale, the chief executive officer directly owned 603,978 shares of the company’s stock, valued at $362,622,351.42. This represents a 0.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 67,195 shares of company stock valued at $37,989,998 in the last 90 days. Corporate insiders own 20.50% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $590.30 on Wednesday. The company has a market cap of $16.48 billion, a P/E ratio of 34.60, a P/E/G ratio of 2.58 and a beta of 1.15. The stock has a 50-day moving average of $541.49 and a two-hundred day moving average of $491.49. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the company earned $3.10 earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.